Breaking News Instant updates and real-time market news.

GKOS

Glaukos

$27.54 /

+1.83 (+7.12%)

09:07
03/24/20
03/24
09:07
03/24/20
09:07

Glaukos provides COVID-19 update, withdraws Q1, FY20 guidance

Glaukos provided an update on the actions it is taking in response to the COVID-19 pandemic. In order to prioritize the health and safety of employees, healthcare professionals, patients and its communities, while continuing to support its customers, Glaukos has acted quickly in recent weeks to implement a number of measures: Health and Safety: In a continuing effort to take steps to protect the health and safety of our workforce and their families and communities, and based on applicable orders and recommendations from federal and local government and health agencies, all employees, with the exception noted below, have been required to work from home. The company has also implemented other measures, such as restricting travel, to protect the health and safety of our customers, their patients and our employees. Maintaining Operations: Consistent with applicable exceptions, Glaukos is maintaining streamlined manufacturing, assembly and other related processes at this time in order to continue providing products to our customers. Glaukos employees involved in such operation-critical processes are organized into a number of small shifts designed to minimize the time any one individual is required to be onsite. For these employees, we have implemented a number of other recommended best practices to protect the health and safety of our workforce. "Our hearts go out to anyone affected by the virus and we are especially grateful for the healthcare providers who are selflessly caring for those who are ill. During these challenging times, our first priority is the health and safety of our employees, customers, patients, providers and the communities in which we operate," said Thomas Burns, Glaukos president and chief executive officer. "While our business may be materially impacted over the short-term as procedures may be temporarily deferred in countries and regions impacted by the COVID-19 outbreak, we have acted proactively to implement several initiatives to best preserve our near-term and future growth opportunities, support our customers and reduce non-essential discretionary spending. These initiatives, paired with our strong current financial position, leave us well-positioned to ultimately provide our essential ophthalmic therapies to customers and their patients who will return for treatment as we move past the peak of this current crisis. I am confident that the longer-term fundamental prospects of our business remain strong and unchanged as we advance our mission to transform the treatment of chronic eye diseases with novel therapies that provide sustainable solutions to important clinical needs." As of December 31, 2019, Glaukos had approximately $183 million in cash and cash equivalents, short-term investments and restricted cash. Additionally, the company does not carry any outstanding debt obligations. Due to the rapidly evolving environment and continued uncertainties from the impact of COVID-19, Glaukos is withdrawing its previously announced first quarter and annual guidance for 2020, which was issued on February 27, 2020. At this date, Glaukos cannot predict the specific extent, or duration, of the impact of the COVID-19 outbreak on its financial and operating results. Glaukos plans to provide additional information, to the extent practicable, during its first quarter earnings call in May.

GKOS Glaukos
$27.54 /

+1.83 (+7.12%)

03/04/20 Citi
Glaukos initiated with a Sell at Citi
02/28/20 JPMorgan
Glaukos downgraded to Neutral on lower than expected growth at JPMorgan
02/28/20 Stephens
Glaukos price target lowered to $69 from $80 at Stephens
02/28/20 JPMorgan
Glaukos downgraded to Neutral from Overweight at JPMorgan

TODAY'S FREE FLY STORIES

Hot Stocks
Gilead announces topline results from Phase 3 SIMPLE trial » 08:44
06/01/20
06/01
08:44
06/01/20
08:44
GILD

Gilead

$77.80 /

+2.43 (+3.22%)

Gilead announced topline…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
GILD Gilead
$77.80 /

+2.43 (+3.22%)

GILD Gilead
$77.80 /

+2.43 (+3.22%)

05/27/20 Raymond James
Raymond James keeps Market Perform on Gilead following Arcus partnership
05/27/20 Wedbush
Arcus Biosciences price target raised to $48 from $40 at Wedbush
05/27/20 Piper Sandler
Piper says partnership more favorable for Gilead than outright Arcus purchase
05/27/20 RBC Capital
Pullback in Gilead stock offers more attractive opportunity, says RBC Capital
GILD Gilead
$77.80 /

+2.43 (+3.22%)

GILD Gilead
$77.80 /

+2.43 (+3.22%)

GILD Gilead
$77.80 /

+2.43 (+3.22%)

GILD Gilead
$77.80 /

+2.43 (+3.22%)

Hot Stocks
Camber Energy, Viking Energy amend merger agreement » 08:44
06/01/20
06/01
08:44
06/01/20
08:44
CEI

Camber Energy

$1.28 /

+0.03 (+2.40%)

Camber Energy and Viking…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CEI Camber Energy
$1.28 /

+0.03 (+2.40%)

Hot Stocks
Rezolute present RZ358 clinical data-validated in PK, glycemic response in HI » 08:43
06/01/20
06/01
08:43
06/01/20
08:43
RZLT

Rezolute

$0.00 /

+ (+0.00%)

Rezolute announced that…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
RZLT Rezolute
$0.00 /

+ (+0.00%)

RZLT Rezolute
$0.00 /

+ (+0.00%)

10/09/19 JMP Securities
Rezolute initiated with an Outperform at JMP Securities
09/09/19 Canaccord
Rezolute initiated with a Buy at Canaccord
Hot Stocks
Ferroglobe announces 'unqualified' audit opinion including going concern » 08:41
06/01/20
06/01
08:41
06/01/20
08:41
GSM

Ferroglobe

$0.71 /

-0.0441 (-5.84%)

Ferroglobe filed its…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
GSM Ferroglobe
$0.71 /

-0.0441 (-5.84%)

GSM Ferroglobe
$0.71 /

-0.0441 (-5.84%)

09/16/19 Stifel
Ferroglobe downgraded to Hold from Buy at Stifel
GSM Ferroglobe
$0.71 /

-0.0441 (-5.84%)

Hot Stocks
Xperi, TiVo announce completion of merger, TIVO no longer listed for trading » 08:41
06/01/20
06/01
08:41
06/01/20
08:41
XPER

Xperi

$13.76 /

-0.36 (-2.55%)

, TIVO

TiVo

$6.21 /

-0.21 (-3.27%)

Xperi Holding announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
XPER Xperi
$13.76 /

-0.36 (-2.55%)

TIVO TiVo
$6.21 /

-0.21 (-3.27%)

XPER Xperi
$13.76 /

-0.36 (-2.55%)

08:21 Today B. Riley FBR
Xperi price target raised to $35 from $31 at B. Riley FBR
05/07/20 Craig-Hallum
Xperi price target lowered to $20 from $25 at Craig-Hallum
02/24/20 B. Riley FBR
Xperi worth 55% more than Metis takeover proposal, says B. Riley FBR
02/19/20 B. Riley FBR
TiVo price target raised to $21 from $19 at B. Riley FBR
TIVO TiVo
$6.21 /

-0.21 (-3.27%)

08:21 Today B. Riley FBR
Xperi price target raised to $35 from $31 at B. Riley FBR
03/12/20 B. Riley FBR
TiVo attractive in uncertain COVID-19 environment, says B. Riley FBR
03/03/20 B. Riley FBR
InterDigital 2020 outlook not at risk from coronavirus, says B. Riley FBR
02/24/20 B. Riley FBR
Xperi worth 55% more than Metis takeover proposal, says B. Riley FBR
XPER Xperi
$13.76 /

-0.36 (-2.55%)

TIVO TiVo
$6.21 /

-0.21 (-3.27%)

TIVO TiVo
$6.21 /

-0.21 (-3.27%)

XPER Xperi
$13.76 /

-0.36 (-2.55%)

TIVO TiVo
$6.21 /

-0.21 (-3.27%)

Hot Stocks
Resideo names Phillip Theodore as Chief Transformation Officer » 08:41
06/01/20
06/01
08:41
06/01/20
08:41
REZI

Resideo

$7.08 /

+0.52 (+7.93%)

Resideo Technologies…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
REZI Resideo
$7.08 /

+0.52 (+7.93%)

REZI Resideo
$7.08 /

+0.52 (+7.93%)

04/28/20 Imperial Capital
Resideo downgraded to In-Line from Outperform at Imperial Capital
04/03/20
Fly Intel: Top five analyst initiations
04/03/20 Roth Capital
Resideo initiated with a Neutral at Roth Capital
02/28/20 Imperial Capital
Resideo upgraded to Outperform from In-Line at Imperial Capital
REZI Resideo
$7.08 /

+0.52 (+7.93%)

Hot Stocks
Equity Residential provides quarter-to-date statistics for Q2 » 08:40
06/01/20
06/01
08:40
06/01/20
08:40
EQR

Equity Residential

$60.57 /

-0.3 (-0.49%)

Equity Residential…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
EQR Equity Residential
$60.57 /

-0.3 (-0.49%)

EQR Equity Residential
$60.57 /

-0.3 (-0.49%)

05/18/20 BofA
BofA upgrades Camden Property to Buy, cuts Equity Residential, Aimco
05/18/20 BofA
Equity Residential downgraded to Neutral from Buy at BofA
05/10/20 Evercore ISI
Equity Residential upgraded to In Line from Underperform at Evercore ISI
04/24/20 Piper Sandler
Equity Residential downgraded to Underweight from Neutral at Piper Sandler
EQR Equity Residential
$60.57 /

-0.3 (-0.49%)

EQR Equity Residential
$60.57 /

-0.3 (-0.49%)

Recommendations
Surmodics price target raised to $76 from $50 at Lake Street » 08:40
06/01/20
06/01
08:40
06/01/20
08:40
SRDX

Surmodics

$37.01 /

-1.42 (-3.70%)

Lake Street analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SRDX Surmodics
$37.01 /

-1.42 (-3.70%)

02/06/20 Barrington
Surmodics price target lowered to $56 from $62 at Barrington
02/06/20 Lake Street
Surmodics upgraded to Buy from Hold at Lake Street
12/11/19 Needham
Surmodics downgraded to Hold from Buy at Needham
11/01/19 Lake Street
Surmodics downgraded to Hold from Buy at Lake Street
SRDX Surmodics
$37.01 /

-1.42 (-3.70%)

Hot Stocks
Resverlogix plans COVID-19 trial program launch » 08:40
06/01/20
06/01
08:40
06/01/20
08:40

Resverlogix announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Hot Stocks
ANI Pharmaceuticals provides update regarding Cortrophin Gel sNDA filing » 08:39
06/01/20
06/01
08:39
06/01/20
08:39
ANIP

ANI Pharmaceuticals

$31.15 /

-0.71 (-2.23%)

ANI Pharmaceuticals…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ANIP ANI Pharmaceuticals
$31.15 /

-0.71 (-2.23%)

ANIP ANI Pharmaceuticals
$31.15 /

-0.71 (-2.23%)

05/08/20 Raymond James
ANI Pharmaceuticals price target lowered to $49 from $65 at Raymond James
05/07/20 Cantor Fitzgerald
Cantor downgrades ANI Pharmaceuticals to Neutral on near-term uncertainty
05/07/20 Cantor Fitzgerald
ANI Pharmaceuticals downgraded to Neutral from Overweight at Cantor Fitzgerald
09/11/19 Guggenheim
ANI Pharmaceuticals initiated with a Buy at Guggenheim
ANIP ANI Pharmaceuticals
$31.15 /

-0.71 (-2.23%)

Hot Stocks
SurveyMonkey announces return to work offering for enterprise customers » 08:38
06/01/20
06/01
08:38
06/01/20
08:38
SVMK

SurveyMonkey

$20.15 /

+0.58 (+2.96%)

SurveyMonkey announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SVMK SurveyMonkey
$20.15 /

+0.58 (+2.96%)

SVMK SurveyMonkey
$20.15 /

+0.58 (+2.96%)

05/18/20 Wells Fargo
Wells upgrades SurveyMonkey to Overweight on resilience, increasing relevance
05/18/20 Wells Fargo
SurveyMonkey upgraded to Overweight from Equal Weight at Wells Fargo
05/14/20 Needham
SurveyMonkey initiated with a Buy at Needham
01/17/20 Wells Fargo
SurveyMonkey price target raised to $21 from $18 at Wells Fargo
SVMK SurveyMonkey
$20.15 /

+0.58 (+2.96%)

SVMK SurveyMonkey
$20.15 /

+0.58 (+2.96%)

SVMK SurveyMonkey
$20.15 /

+0.58 (+2.96%)

Hot Stocks
Iterum Therapeutics evaluating corporate, strategic, financial alternatives » 08:37
06/01/20
06/01
08:37
06/01/20
08:37
ITRM

Iterum Therapeutics

$4.23 /

-0.14 (-3.20%)

Based on the trial…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ITRM Iterum Therapeutics
$4.23 /

-0.14 (-3.20%)

ITRM Iterum Therapeutics
$4.23 /

-0.14 (-3.20%)

01/21/20 Gabelli
Iterum Therapeutics downgraded to Sell from Buy at Gabelli
12/11/19 RBC Capital
Iterum Therapeutics price target lowered to $10 from $14 at RBC Capital
12/11/19 SVB Leerink
Iterum Therapeutics downgraded to Market Perform from Outperform at SVB Leerink
06/21/19 H.C. Wainwright
Iterum Therapeutics initiated with a Buy at H.C. Wainwright
ITRM Iterum Therapeutics
$4.23 /

-0.14 (-3.20%)

Hot Stocks
Iterum says Phase 3 trial of sulopenem did not meet primary endpoint » 08:37
06/01/20
06/01
08:37
06/01/20
08:37
ITRM

Iterum Therapeutics

$4.23 /

-0.14 (-3.20%)

Iterum Therapeutics…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ITRM Iterum Therapeutics
$4.23 /

-0.14 (-3.20%)

ITRM Iterum Therapeutics
$4.23 /

-0.14 (-3.20%)

01/21/20 Gabelli
Iterum Therapeutics downgraded to Sell from Buy at Gabelli
12/11/19 RBC Capital
Iterum Therapeutics price target lowered to $10 from $14 at RBC Capital
12/11/19 SVB Leerink
Iterum Therapeutics downgraded to Market Perform from Outperform at SVB Leerink
06/21/19 H.C. Wainwright
Iterum Therapeutics initiated with a Buy at H.C. Wainwright
ITRM Iterum Therapeutics
$4.23 /

-0.14 (-3.20%)

Recommendations
Canopy Growth price target lowered to C$24 from C$30 at Alliance Global Partners » 08:37
06/01/20
06/01
08:37
06/01/20
08:37
CGC

Canopy Growth

$17.36 /

-4.37 (-20.11%)

Alliance Global Partners…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CGC Canopy Growth
$17.36 /

-4.37 (-20.11%)

CGC Canopy Growth
$17.36 /

-4.37 (-20.11%)

06:30 Today BMO Capital
Canopy Growth downgraded to Market Perform from Outperform at BMO Capital
06:26 Today CIBC
Canopy Growth downgraded to Neutral from Outperformer at CIBC
05:37 Today Stifel
Stifel double downgrades Canopy Growth to Sell on 'course correction'
05:30 Today CIBC
Canopy Growth downgraded to Neutral from Outperformer at CIBC
CGC Canopy Growth
$17.36 /

-4.37 (-20.11%)

CGC Canopy Growth
$17.36 /

-4.37 (-20.11%)

CGC Canopy Growth
$17.36 /

-4.37 (-20.11%)

CGC Canopy Growth
$17.36 /

-4.37 (-20.11%)

Hot Stocks
Anixa Biosciences, OntoChem synthesize four potential COVID-19 compounds » 08:37
06/01/20
06/01
08:37
06/01/20
08:37
ANIX

Anixa Biosciences

$2.29 /

-0.005 (-0.22%)

Anixa Biosciences…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ANIX Anixa Biosciences
$2.29 /

-0.005 (-0.22%)

ANIX Anixa Biosciences
$2.29 /

-0.005 (-0.22%)

12/30/19 B. Riley FBR
Anixa Biosciences price target lowered to $8 from $11.25 at B. Riley FBR
Hot Stocks
Eldorado Resorts to open 3 Missouri casinos, 2 Iowa casinos » 08:36
06/01/20
06/01
08:36
06/01/20
08:36
ERI

Eldorado Resorts

$35.52 /

+0.79 (+2.27%)

Eldorado Resorts…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ERI Eldorado Resorts
$35.52 /

+0.79 (+2.27%)

ERI Eldorado Resorts
$35.52 /

+0.79 (+2.27%)

05/12/20 Deutsche Bank
Eldorado Resorts price target lowered to $28 from $68 at Deutsche Bank
05/12/20 Jefferies
Eldorado Resorts price target raised to $38 from $29 at Jefferies
04/17/20 SunTrust
Caesars, Twin River Worldwide upgraded to Buy from Hold at SunTrust
04/06/20 Jefferies
Eldorado has 'considerable upside' from Caesars merger, says Jefferies
ERI Eldorado Resorts
$35.52 /

+0.79 (+2.27%)

ERI Eldorado Resorts
$35.52 /

+0.79 (+2.27%)

ERI Eldorado Resorts
$35.52 /

+0.79 (+2.27%)

ERI Eldorado Resorts
$35.52 /

+0.79 (+2.27%)

Recommendations
Burlington Stores price target raised to $250 from $184 at RBC Capital » 08:36
06/01/20
06/01
08:36
06/01/20
08:36
BURL

Burlington Stores

$209.70 /

-3.735 (-1.75%)

RBC Capital analyst Kate…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BURL Burlington Stores
$209.70 /

-3.735 (-1.75%)

BURL Burlington Stores
$209.70 /

-3.735 (-1.75%)

05/29/20 DA Davidson
Burlington Stores price target raised to $250 from $215 at DA Davidson
05/29/20 Loop Capital
Burlington Stores price target lowered to $250 from $265 at Loop Capital
05/29/20 Citi
Burlington Stores price target raised to $250 from $205 at Citi
05/11/20 Nomura Instinet
Burlington Stores price target raised to $190 from $170 at Nomura Instinet
BURL Burlington Stores
$209.70 /

-3.735 (-1.75%)

BURL Burlington Stores
$209.70 /

-3.735 (-1.75%)

BURL Burlington Stores
$209.70 /

-3.735 (-1.75%)

Hot Stocks
EIB, Voxeljet expand partnership to bring 3D printing into series production » 08:36
06/01/20
06/01
08:36
06/01/20
08:36
VJET

Voxeljet

$1.12 /

-0.02 (-1.75%)

Voxeljet announced that…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
VJET Voxeljet
$1.12 /

-0.02 (-1.75%)

VJET Voxeljet
$1.12 /

-0.02 (-1.75%)

10/29/19 Piper Jaffray
Piper 3D printing survey brings better feedback in Q3
08/18/19 Piper Jaffray
Voxeljet price target lowered to $3 from $4.75 at Piper Jaffray
Hot Stocks
Revance, Mylan to advance development program for Botox biosimilar » 08:35
06/01/20
06/01
08:35
06/01/20
08:35
RVNC

Revance

$20.88 /

-0.46 (-2.16%)

, MYL

Mylan

$17.10 /

-0.15 (-0.87%)

Revance Therapeutics…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
RVNC Revance
$20.88 /

-0.46 (-2.16%)

MYL Mylan
$17.10 /

-0.15 (-0.87%)

RVNC Revance
$20.88 /

-0.46 (-2.16%)

03/27/20 H.C. Wainwright
Revance price target lowered to $24 from $28 at H.C. Wainwright
03/23/20
Fly Intel: Top five analyst downgrades
03/22/20 Goldman Sachs
Revance downgraded to Neutral from Buy at Goldman Sachs
02/26/20 H.C. Wainwright
Revance price target raised to $28 from $23 at H.C. Wainwright
MYL Mylan
$17.10 /

-0.15 (-0.87%)

03/25/20 Cantor Fitzgerald
Few concerns weighing on Mylan shares today, says Cantor Fitzgerald
02/06/20 BMO Capital
Biogen price target raised to $317 from $297 at BMO Capital
02/05/20 Baird
Biogen price target raised to $290 from $250 at Baird
02/05/20 Mizuho
Biogen's Tecfidera win worth $15-$30 per share to DCF, Mizuho says
RVNC Revance
$20.88 /

-0.46 (-2.16%)

MYL Mylan
$17.10 /

-0.15 (-0.87%)

MYL Mylan
$17.10 /

-0.15 (-0.87%)

MYL Mylan
$17.10 /

-0.15 (-0.87%)

MYL Mylan
$17.10 /

-0.15 (-0.87%)

Hot Stocks
Twin River Worldwide to open nearly entire portfolio of operating casinos » 08:35
06/01/20
06/01
08:35
06/01/20
08:35
TRWH

Twin River Worldwide

$20.95 /

+0.24 (+1.16%)

Twin River Worldwide…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TRWH Twin River Worldwide
$20.95 /

+0.24 (+1.16%)

TRWH Twin River Worldwide
$20.95 /

+0.24 (+1.16%)

05/29/20 SunTrust
Twin River Worldwide price target raised to $25 from $20 at SunTrust
04/17/20 SunTrust
Caesars, Twin River Worldwide upgraded to Buy from Hold at SunTrust
04/17/20 SunTrust
Twin River Worldwide upgraded to Buy from Hold at SunTrust
02/12/20 SunTrust
Twin River Worldwide price target raised to $31 from $26 at SunTrust
TRWH Twin River Worldwide
$20.95 /

+0.24 (+1.16%)

General news
Oil Action: July WTI crude » 08:35
06/01/20
06/01
08:35
06/01/20
08:35

Oil Action: July WTI…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Recommendations
WNS Holdings elevated to Fresh Pick at Baird » 08:34
06/01/20
06/01
08:34
06/01/20
08:34
WNS

WNS Holdings

$48.37 /

+0.13 (+0.27%)

Baird analyst David…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
WNS WNS Holdings
$48.37 /

+0.13 (+0.27%)

WNS WNS Holdings
$48.37 /

+0.13 (+0.27%)

04/24/20 Deutsche Bank
WNS Holdings price target lowered to $56 from $81 at Deutsche Bank
04/23/20 Needham
WNS Holdings downgraded to Buy from Strong Buy at Needham
04/21/20 Cowen
WNS Holdings price target lowered to $57 from $77 at Cowen
04/17/20 Wells Fargo
WNS Holdings downgraded to Equal Weight from Overweight at Wells Fargo
WNS WNS Holdings
$48.37 /

+0.13 (+0.27%)

Hot Stocks
Cancer Genetics: 'Substantial doubts' about ability continue as going concern » 08:33
06/01/20
06/01
08:33
06/01/20
08:33
CGIX

Cancer Genetics

$3.10 /

+0.14 (+4.73%)

The company said,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
CGIX Cancer Genetics
$3.10 /

+0.14 (+4.73%)

CGIX Cancer Genetics
$3.10 /

+0.14 (+4.73%)

Hot Stocks
Equinix acquires 13 data centers across Canada from BCE for $750M in cash » 08:32
06/01/20
06/01
08:32
06/01/20
08:32
EQIX

Equinix

$698.03 /

+4.68 (+0.67%)

, BCE

BCE

$41.50 /

+0.125 (+0.30%)

Equinix (EQIX) announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
EQIX Equinix
$698.03 /

+4.68 (+0.67%)

BCE BCE
$41.50 /

+0.125 (+0.30%)

EQIX Equinix
$698.03 /

+4.68 (+0.67%)

05/13/20 RBC Capital
Equinix price target raised to $706 from $688 at RBC Capital
05/07/20 Wells Fargo
Equinix price target raised to $745 from $675 at Wells Fargo
05/07/20 JPMorgan
Equinix price target raised to $725 from $675 at JPMorgan
04/27/20 JPMorgan
JPMorgan positive on data center demand, Equinix top large cap pick
BCE BCE
$41.50 /

+0.125 (+0.30%)

05/08/20 CIBC
BCE price target lowered to C$61 from C$63 at CIBC
05/08/20 Canaccord
BCE price target raised to C$59 from C$58 at Canaccord
04/30/20 Scotiabank
BCE price target lowered to C$63 from C$64.50 at Scotiabank
04/07/20 Veritas
BCE downgraded to Sell from Buy at Veritas
EQIX Equinix
$698.03 /

+4.68 (+0.67%)

BCE BCE
$41.50 /

+0.125 (+0.30%)

EQIX Equinix
$698.03 /

+4.68 (+0.67%)

EQIX Equinix
$698.03 /

+4.68 (+0.67%)

Hot Stocks
FDA grants EUA for COVID-19 test that Aytu BioScience distributes » 08:32
06/01/20
06/01
08:32
06/01/20
08:32
AYTU

Aytu BioScience

$1.48 /

+0.09 (+6.47%)

Aytu BioScience announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AYTU Aytu BioScience
$1.48 /

+0.09 (+6.47%)

AYTU Aytu BioScience
$1.48 /

+0.09 (+6.47%)

05/29/20 H.C. Wainwright
Aytu BioScience initiated with a Buy at H.C. Wainwright
09/18/19 Ladenburg
Aytu BioScience price target raised to $4.75 from $4.00 at Ladenburg
AYTU Aytu BioScience
$1.48 /

+0.09 (+6.47%)

AYTU Aytu BioScience
$1.48 /

+0.09 (+6.47%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.